CN100500219C - Anti tumour medicinal composition containing platinum compound - Google Patents

Anti tumour medicinal composition containing platinum compound Download PDF

Info

Publication number
CN100500219C
CN100500219C CNB2005100422610A CN200510042261A CN100500219C CN 100500219 C CN100500219 C CN 100500219C CN B2005100422610 A CNB2005100422610 A CN B2005100422610A CN 200510042261 A CN200510042261 A CN 200510042261A CN 100500219 C CN100500219 C CN 100500219C
Authority
CN
China
Prior art keywords
platinum
tumor
compounds
combination
cisplatin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB2005100422610A
Other languages
Chinese (zh)
Other versions
CN1686554A (en
Inventor
孔庆忠
孙娟
宋邦强
左昌儒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DASEN BIOLOGICAL PHARMACEUTICAL CO., LTD.
Original Assignee
Shandong Lanjin Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Lanjin Pharmaceuticals Co Ltd filed Critical Shandong Lanjin Pharmaceuticals Co Ltd
Priority to CNB2005100422610A priority Critical patent/CN100500219C/en
Publication of CN1686554A publication Critical patent/CN1686554A/en
Application granted granted Critical
Publication of CN100500219C publication Critical patent/CN100500219C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A composite medicine for treating solid tumor by locally putting it in the tumor is composed of the active anticancer components (Pt compound and its synergist choosen from taxol-type anticancer medicine, antineoplastic antibiotic and antimetabolitic medicine), and the medicinal auxiliary (biocompatible and biodegradable high-molecular polymer).

Description

A kind of entity-tumor-resistant medicine composition that contains platinum-like compounds
(1) technical field
The present invention relates to a kind of entity-tumor-resistant medicine composition, belong to technical field of pharmaceuticals.
(2) background technology
Treatment for cancer mainly comprises methods such as operation, radiotherapy and chemotherapy.In used various chemotherapeutics, the action effect of platinum-like compounds is comparatively obvious, has been widely used in multiple malignant tumor.Because platinum-like compounds is to suppress synthetic its antitumor action of bringing into play of RNA by combining with DNA, and the DNA repair function in many tumor cells obviously increases after treatment, so effectively reduce or suppress the emphasis that the interior DNA repair function of tumor cell just becomes current research.
Recent findings, deactivation or suppress intracellular dna repair protein and can strengthen the sensitivity of part tumor cell to chemotherapy, referring to " 06-benzyl guanine analog is to the effect of human tumor cells to the cell toxicant sensitivity of alkylating agent " " cancer research " 51 phase 3367-3372 pages or leaves (1991) such as Doran (Dolan et al., Cancer Res., 51,3367-3372,1991)).Yet, blood vessel in the mesenchyma stroma of tumors, connective tissue, stromatin, fine micro protein and collagen protein etc. not only provide support and requisite nutrient substance for the growth of tumor cell, also influenced chemotherapeutics around tumor and infiltration and diffusion in the tumor tissues, " situation of extracellular matrix is to the influence of medicine running in the entity tumor " " cancer research " 60 phase 2497-503 page or leaf (2000) (Netti PA such as carry referring to the Buddhist nun, Cancer Res.2000,60 (9): 2497-503).Because entity tumor excessive expansion hypertrophy, the viscosity of matter was high than its normal surrounding tissue all between matter pressure, tissue elasticity pressure, fluid pressure reached therebetween, therefore, conventional chemotherapy, be difficult to tumor by local and form effective drug level, referring to " placing cisplatin adding system carmustine treatment rat brain tumor in the tumor " " surgery tumor magazine " 69 phase 76-82 pages or leaves (1998) (Kong Q et al., J Surg Oncol.1998 Oct such as Kong Qingzhongs; 69 (2): 76-82), improve the restriction that dosage is subjected to general reaction again merely.
In addition, the cancer drug therapy of low dosage not only can increase the Drug tolerance of cancerous cell, but also can promote the growth of its wettability "; referring to beam etc. " increased after the cancer therapy drug pulse screening human lung carcinoma cell Drug tolerance and external invade the profit ability and with the change of gene expression " " international journal of cancer " 111 phase 484-93 page or leaf (2004) (Liang Y; et al., Int J Cancer.2004; 111 (4): 484-93).
Because the principal element of decision therapeutic effect is the drug level of tumor by local and the tumor cell sensitivity to medicine.And the blood vessel in the mesenchyma stroma of tumors, connective tissue, stromatin, fine micro protein and collagen protein etc. not only provide support and requisite nutrient substance for the growth of tumor cell, have also influenced chemotherapeutics around tumor and infiltration and diffusion in the tumor tissues.
(3) summary of the invention
The present invention is directed to the deficiencies in the prior art, a kind of entity-tumor-resistant medicine composition is provided.
Entity-tumor-resistant medicine composition comprises anticancer effective component and pharmaceutic adjuvant, and wherein anticancer effective component is platinum-like compounds and platinum-like compounds synergist.Wherein, the platinum-like compounds synergist is one of paclitaxel kind anti-cancer drugs thing, antitumor antibiotics or antimetabolitas or combination.
Above-mentioned platinum-like compounds is selected from one of following or combination:
Cisplatin (cisplatin, DDP), carboplatin (Carboplatin, carboplatin), heptan platinum, DNA-2114, enloplatin (Enloplatin), sulfatodiamino cyclohexane platinum (ring ethylenediamine platinic sulfate), Spiroplatin (spiral shell sulphur platinum amine), dexormaplatin (Dexormaplatin), iproplatin (Iproplatin), lobaplatin (Lobaplatin), rice platinum (Miboplatin), nedaplatin (Nedaplatin), ormaplatin (0rmaplatin), oxaliplatin (Oxaliplatin), sebriplatin (Sebriplatin), spiroplatin (Spiroplatin) or zeniplatin (Zeniplatin).
Above platinum-like compounds with cisplatin, carboplatin, dexormaplatin, heptan platinum or oxaliplatin serve as preferred.
The percentage by weight of above-mentioned platinum-like compounds in compositions is 0.1%-60%, is good with 1%-50%, and 5%-30% is best.
Be selected from one of following or combination as the paclitaxel kind anti-cancer drugs thing (taxanes) of platinum-like compounds synergist:
Paclitaxel (Paclitaxel, taxol, taxol), Docetaxel (Docetaxel, taxotere, docetaxel) and the derivant of paclitaxel, as, but be not limited to, 2 '-hydroxyl taxol (paclitaxel-2 '-hydroxy), 10-removes acetyl Baccatine III (10-deacetylbaccatin III, DAB), 14 beta-hydroxies-10-removes acetyl Baccatine III (14-OH-DAB), 9-dihydro-13-Baccatine III (DHB), IDN5109,10-removes acetyl taxol (10-deacetyltaxol), 7-table-taxol (7-epi-taxol), Tetraol, Baccatine III (baccatin III), Tetraol V, Semen Caesalpiniae Ramulus et folium taxi cuspidatae (Taxus brevifolia), ground hemlock (Taxus Canadensis), yew (Taxus baccata) and Chinese Ramulus et folium taxi cuspidatae (Taxus chinensis), pointed tooth Ramulus et folium taxi cuspidatae (Taxus cuspidata), cultivate Ramulus et folium taxi cuspidatae (Taxus X media cultivars), Yunnan Ramulus et folium taxi cuspidatae Taxus yunnanensis) or Florida Ramulus et folium taxi cuspidatae (Taxus floridana), or their salt, as, but be not limited to sulfate, phosphate, hydrochlorate, Lactobionate, acetate, aspat, nitrate, citrate, purine or pyrimidine salt, succinate or maleate.
Above-mentioned paclitaxel kind anti-cancer drugs thing serves as preferred with paclitaxel, Docetaxel (docetaxel) or 2 '-hydroxyl taxol, and the content in compositions is the 1-50% percentage by weight.
Suppress by combining that RNA is synthetic to be used for the treatment of various cancers as the antitumor antibiotics of platinum-like compounds synergist with DNA.
Antitumor antibiotics is selected from one of following or combination: carcinomycin, bleomycin (Bleomycin, Bleomycin A5, Pingyangmycin), (hydrochloric acid) bleomycin, zorbamycin, the piperazine bleomycin, sulphuric acid piperazine bleomycin, antibiotic 1588, bouvardin, clarithromycin (Clarithromycin), aklavine (Aclacinomycin A, aclarubicin), aklavine-B, 9-[4-(N-Methylacetamido)anilino, 9-(4-(N-Methylacetamido)anilino)-7-methyl-1H-imidazo(4,5-f)quinoline, kidamycin, acetylkitamycin (acetyl kidamycin), azotomycin (azotomycin), daunomycin (rubidomycin, daunorubicin, daunomycin), Diacetoxysciroenol (Diacetoxysciroenol), doxorubicin hydrochloride (doxorubicin, doxorubicin, adriamycin), triferricdoxorubicin, epirubicin (epiadriamycin) or epirubicin (Epirubicin), Valrubicin (valrubicin), pirarubicin, 7-O-methyl Nuo Jia-4 '-epirubicin (7-o-methylnogallol-4 '-epiadriamycin), diethoxy acetyl amycin, ciclamicin, mitomycin (Mitomycin), ametycin (mitomycin C), NSC-69529, actinomycin D (Dactinomycin), actinomycin C, cyclosporin A, Carzinocidin (carzinocidin), carzinophillin (carzinophylin), cardinophyllin, the tumor rhzomorph, carzinostatin (carzinostatin, carcinostain), neocarzinostain NCS (neocarzinostain), diazamycine (diazamycine), Macrocin (macrocin), macrocinomycin (macrocinomycin), dactinomycin, alanopsin, alazopeptin, the A Le lid, neothricin (neothricin, neothramycin), macromycin (macromomycin or macromycin), neothramycin A, nocardin (nocardin), nocardorubin. (nocardorubin), 2-[N-(2-amidinoethyl)carbamoyl (noformicin), nogalamycin (promise Garamycin, nogalamycin or nogaromycin), Mitochromine mitocromine B-35251 (mitochromine or mitocromine), polymyxin E (Polymyxin E), pirlimycin (Pirlimycin), dirithromycin (Dirithromycin), antramycin, oxalysine, duazomycin, Olivomycin, rufocromomycin, NSC-45384, streptozotocin, peplomycin, puromycin, sparsomycin, talisomycin, Anthrapyrazole, losoxantrone (Losoxantrone), mitoxantrone (Mitoxantrone), piroxantrone (Piroxantrone), teloxantrone (Teloxantrone), hydroxyl nitre D-glucosamine ring element, anthramycin (anthramycin, antramycin), methylanthramycin, Ai Fei ground can be peaceful, asperlin, (hydrochloric acid) Carrninomycin I, talisomycin, macromycin, O-Demethyldaunomycin, NSC-178248, chromomycin A3, chlorine assistant star (chlorozotocin), demethylrifampicin, ditrisarubicins, Hitachimycin, deoxycoformycin, puromycin, puromycin hydrochloride, rachelmycin, rebeccamycin, Sangivamycin, sarkomycin, sibiromycin, talisomycin, rice holder Zuro, selenazofurin, Antibiotic BMG-162aF2, spirogermanium hydrochloride, Spirogermanium, Spirophydantoin Mustard or stibcytostatum.
Above-mentioned antitumor antibiotics serves as preferred with bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star.
Antimetabolitas as the platinum-like compounds synergist can stop the synthetic of DNA in different links respectively, suppresses the cell division increment, and cell cycle and DNA are synthetic to play a role by influencing.
Above-mentioned antimetabolite is selected from one of following or combination:
Pemetrexed (Alimta), pemetrexed disodium, Rumi Qu Sai, doxifluridine (Doxifloridine, fortulon), the 5-doxifluridine, floxuridine (fluridine), propylthiouracil, fluorouracil (Fluoracil, Fluracil), the fluorobutane uracil, 5-fluorouracil (Fluorouracil, 5-FU), tegadifurum, the 5-fluoxydin, sulfomercaprine sodium, mercaptopurine (Mercaptopurine, happy disease is peaceful, 6-MP), mercapto miaow purine, Ismipur, the adenine hydrochlorate, Benin, thioguanine (thioguanine, 6-TG), sulfur crow purine, tisupurin, Hydrazinium sulfate, dianhydrogalactitol, Aziridinyl Benzoquinone, but sweet smell Luoning, isoeuxanthone, chalone, chlorine is bent phosphoric acid, clastoban, cycloleucine, look into the Chinese holly woods, methyl yellow is looked into the Chinese holly woods sourly, Bai Ruikuaer, oxipurinol, Australia Ma Lite, bromine crust acid (sodium), Brytoslatin-I, bromine urea glycosides, the fluorine urea is amine, folic acid, methotrexate (methotrexate, MTX), 10-ethyl denitrification aminopterin (deaza-aminopterin), fluoromethotrexate, the dioxy methotrexate, 5, the 10-lonetrexol, N5-Methyltetrahydrohmofotic Acid, buthiopurin, his amide of Dinke, Guang azepine crow glycosides, carmofur (Carmofur), ftorafur (Tegafur, tegafur, FT-207), Tegafur-uracil mixt., 6-prenylindole, 6-thioinosine, UFT (Tegafur-Uracil, UFT), coralyne, N-foymylsarcolysin, ammonia (base) pterin (aminopterin), aminopterin sodium (Aminopterin Sodium), 8-azaguanine (8-azaguanine), 6-dimethylamino-8-azaadenosine, (nitro) imuran (azathioprine), uracil, 5-mercaptomethyluracil, azaserine (azaserine), Raltitrexed (Raltitrexed), nolatrexed dihydrochloride, sophoridine, formyl tetrahydrofolic acid, 5-methyltetrahydrohomofolate, Zoledronate, thunder accounts for for song, the temozolomide, bicalutamide, asparaginase (L-Asparaginase, left-handed asparagine), calcium levofolinate, calcium folinate (Calcium Levofolinate, calcium leucovorin), Quinespar, triazinate, trimetrexate, tramadol, the 5-chlorobarbituric acid, 5-diazonium uracil, piracetam, hycamtin, topotecan hydrochloride, ZD-9331, BHAC, SM108, cytosine arabinoside (cytosine arabinoside, Cytarabine (Ara-C)), ancitabine (cyclotidine, Cyclocytidine), hydroxyurea (Hydroxycarbamide, hydroxyurea), the hydroxyl guanidine, the 5-fluorouracil nucleoside, the 5-fluorouracil deoxynucleoside claims fluorouracil deoxynucleoside (floxuridine) again, glycerol Citrus chachiensis Hort. alkali, A Lei can loose, HCFU, 5 ' DFUR, TK-177, isoxazole acetic acid, aminoglutethimide (ethylbenzene amine piperidones, aminoglutethimidium, aminoglutethimide), amonafide, 5-chloro-5-deoxyarabinosylcytosine, atamestane, azacytidine (Azacitidine, 5-azacytidine, the atropic cytidine, AzGR), chloramphenalan (betamerphalan, Betamerphalan), decitabing, dexrazoxane (Dexrazoxane), crisnatol, cristatic acid, carat is sharp flat, the sharp guest of carat, galocitabine (Galocitabine), gemcitabine (Gemcitabine), ibacitabine (Ibacitabine), enocitabine (Enocitabine), ancitabine (Ancitabine), decitabine (Decitabine), flurocitabine (Flurocitabine), capecitabine (Capecitabine), enocitabine, his shore of imidazoles, the non-Shandong of Crane, the OK a karaoke club amide, carzolamide, carbazylquinone, CB-1-252, curcumin, the curcumin diketone, ketotrexate, trimetrexate, Si Poguning, deoxidation Si Poguning, naphthalene urea phosphamide, Ditercalinium Chloride, F-ara AMP-2, fluorine benzyl thiophene ketone, gamlogic acid, goserelin, nitrogen Chinese holly mountain range, Hellebrigenin, inosine dialdehyde, metoprine, mitobronitol (Dibromomannitol, Mitobronitol), mitolactol (Mitolactol), Ke is for ground, Persian, eriolangin, dopan (Chlorethylaminouracil, Dopan), Mei Luogerui, Methyl GAG, GR 30921X, mitotane, fazarabine (Fazarabine), fludarabine (fludarabine), cladribine (cladribine), pentoside (pentostatin), phenaline, benzene comes U.S. special, phosphemide, hair Buddhist nun azoles, Polyprenic Acid, Pteroylaspartic Acid, pteroyltriglutamic acid, fast rice tongue pool, riboprine, simtrazene, Schizophyllan, sodium bromebrate, Solvent Yellow 3, bent fourth sulphur ester, TEM, triaziquone, triciribine, TCN-P NSC-280594, triptolide, triptorelin, nine cloth Lip river azoles, UFT, vitamin B-17, Wei Maining, z-azepine adenosine, prick western cytidine, epipropidine (Epipropidine), the A Monuo phase, adozelesin (Adozelesin), acronine (Acronine), alanosine (Alanosine), ametantrone (Ametantrone), Anastrozole, the A Naxi army, anaxirone (Anaxirone), A Si Yin wakes up, acivicin (Acivicin), atevirdine (Atevirdine), idoxifene (idoxifene), AT-236, hold high and rather study carefully Ji, individual Lu Dabuxin, antineoplaston, antineoplastons, asaphan, Aspargus Granule, AT-346, Bai Ruikuaer (sodium), (hydrochloric acid) Orang Crush, granisetron, tropisetron, dacarbazine, ondansetron, thymosin, tramadol, imatinib mesylate, diclofenac, Thalidomide, the holder fluorine kills star, toremifene, ambroxol, lappaconitine, anti-general etc. because of, thymosin, flutamide, ethyliminum, amine benzene, neoquini oxydum, the N-methylformamide, the jail can reach azoles, NSC-56045, oxisuran, oxylycorine, paphencyl, it is fixed to moor damp Nip, the penberol, prospidine chloride, protoanemonin, good generation born of the same parents, retelliptine, Sensorad, M3, solapalmitine, solaziquonum, stibenemidine, Temozoromide, the many Shillongs of platform, thiaolivacine, bifurcation pyridine of nitre ammonia or SN-11841.
Above-mentioned antimetabolite is with Ismipur, 5-fluorouracil (5-FU), pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, cladribine or pentoside are preferred.
To suppress RNA synthetic by combining with DNA for platinum-like compounds in the entity-tumor-resistant medicine composition of the present invention, thereby be used for the treatment of various cancers, the platinum-like compounds synergist is used for the treatment of outside the various cancers, also can effectively reduce or suppress the DNA repair function in the tumor cell, and then increase the sensitivity of tumor cell platinum-like compounds.
Platinum-like compounds synergist shared percentage by weight in compositions is decided because of concrete condition, generally speaking, can be good with 1%-50% from 0.01%-80%, is the best with 5%-30%.The weight ratio of platinum-like compounds and platinum-like compounds synergist is that 1-9:1 is to 1:1-9.
Pharmaceutic adjuvant of the present invention can be through enzyme, soda acid or tissue fluid hydrolysis or degraded, comprises one of following or its combination:
(1) biocompatibility polymer, comprise biodegradable or biological nondegradable polymer and composition thereof or copolymer, (2) water-soluble low-molecular chemical compound is or/and (3) are used to realize the suitable additive and the excipient of pharmaceutical dosage forms such as injection and slow releasing agent.
Above-mentioned biodegradable polymer comprises natural and/or synthetic polymer.Synthetic polymer as, but be not limited to, polyanhydrides, polyhydroxy acid, polyester (polyesters), polyamide (polyamides), polypeptide (polypeptides), polyactide (polylactides) is as polylactic acid (polylactic acid), polyactide and glycolide copolymer (as the copolymer (PLGA) of glycolic and lactic acid), poe (polyorthoesters), polyphosphazene (polyphosphazenes), to carboxy phenyl propane (p-CPP), certain herbaceous plants with big flowers diacid (sebacic acid), liposome, Polyethylene Glycol (polyglycolide) (polymer of hydroxyacetic acid and lactic acid), carboxylic acids (carboxylic acids), fatty acid (fatty acids), phospholipid (phospholipids), nucleic acid (nucleic acids), polyamino acid (polyamino acids), aminoacid such as phenylalanine (phenylalanine), tyrosine (tyrosine), different bright (isoleucine), polynucleotide (polynucleotides); Natural polymer as, but be not limited to, protein and polysaccharide (polysaccharides) comprise hyaluronic acid (hyaluronic acid), chondroitin sulfate (chondroitin sulfate), collagen protein, gelatin, albumin etc.Wherein, preferred polymer is polyactide, Polyethylene Glycol or polyactide and glycolide copolymer (as the copolymer (PLGA) of glycolic and lactic acid).
Above-mentioned polyanhydrides can be selected for use, but is not limited to, fragrant polyanhydride, aliphatic polyanhydride; Wherein fragrant polyanhydride will be separated slower, the fusing point height, and dissolubility is low in the organic solvent, however the copolymer of fragrant polyanhydride and aliphatic polyanhydride is comparatively desirable (United States Patent (USP) 4757128) but.Representative wherein is polifeprosan (to the copolymer of carboxy phenyl propane (p-CPP) and certain herbaceous plants with big flowers diacid (SA)), and is fragrant polyanhydride to carboxy phenyl propane, and the certain herbaceous plants with big flowers diacid then is the copolymer of an aromatic diacid and a fat diacid.The copolymer of available other fragrance or aliphatic polyanhydride has a detailed description in other United States Patent (USP) that (US 4857311; 4888176; 4789724).
Above-mentioned polyhydroxy acid can be selected for use: the copolymer (PLGA) of mixture, glycolic and the lactic acid of polylactic acid (PLA), polyglycolic acid (PGA), polylactic acid and polyglycolic acid.Above polyhydroxy acid can singly select or multiselect, and when singly selecting, the molecular weight of polylactic acid can be, and 5000～100,000, with 10,000～50,000 is preferred, with 10,000～30,000 for most preferably; The molecular weight of polyglycolic acid can be, but is not limited to, and 5000～100,000, but with 10,000～50,000 is preferred, and with 10,000～20,000 for most preferably; The molecular weight of the copolymer of glycolic and lactic acid can be, but is not limited to, and 1000～100,000, but with 10,000～50,000 is preferred; With 10,000～20,000 for most preferably; When multiselect, compound polymer or the copolymer formed with macromolecule polymer or different macromolecule polymer serve as preferred, with the compound polymer that contains different molecular weight polylactic acid or certain herbaceous plants with big flowers diacid or copolymer for most preferably, as, but be not limited to, molecular weight is 5000 to 10000 polylactic acid with molecular weight is that 20000 to 50000 polylactic acid mixes, molecular weight is 10000 to 20000 polylactic acid with molecular weight is that 30000 to 80000 PLGA mixes, molecular weight is that 5000 to 10000 polylactic acid mixes with the certain herbaceous plants with big flowers diacid, molecular weight is that 30000 to 80000 PLGA mixes with the certain herbaceous plants with big flowers diacid.When PLA and PGA mixing, its content percentage by weight is respectively 0.1-99.9% and 99.9-0.1%.Compositions can discharge effective ingredient by the mode of direct diffusion and/or degraded.Above molecular weight peak value scope is that GPC records.
The nondegradable polymer of above-mentioned biology comprises, but be not limited to: polyethylene propylene (polyvinyl propylene), polyvinylpyrrolidone (polyvinylpyrrolidone, PVP), organosilicon polymer, ethylene vinyl acetate copolymer (Ethelene-vinyl acetate copolymer, EVAc), polyacrylonitrile (polyacrylonitriles), polyurethanes (polyurethanes), silicone (silicone) and polyphosphazene (polyphosphazenes) etc.Compositions can discharge effective ingredient by the mode of direct diffusion.
For regulating other characteristic of drug releasing rate or change entity-tumor-resistant medicine composition of the present invention, can change the composition and the proportioning of monomer component or molecular weight, interpolation or the adjusting pharmaceutic adjuvant of polymer, add the water-soluble low-molecular chemical compound, as, but be not limited to various sugar or salt etc.Wherein sugar can be, but is not limited to, xylitol, oligosaccharide and chitin etc., and wherein salt can be but is not limited to, potassium salt or sodium salt etc.
The used pharmaceutic adjuvant of entity-tumor-resistant medicine composition of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, but with the high molecular weight water soluble polymer is main separation, in various high molecular polymers, with polylactic acid, certain herbaceous plants with big flowers diacid, the mixture or the copolymer that contain the macromolecule polymer of polylactic acid or certain herbaceous plants with big flowers diacid is first-selection, mixture and copolymer can be selected from, but be not limited to the mixture or the copolymer of the mixture of PLA, PLGA, PLA and PLGA, certain herbaceous plants with big flowers diacid and fragrant polyanhydride or aliphatic polyanhydride.Polylactic acid (PLA) and polyglycolic acid the blend ratio be 10/90-90/10 (weight), 25/75-75/25 (weight) preferably.The method of blend is arbitrarily.Content when glycolic and lactic acid copolymerization is respectively percentage by weight 10-90% and 90-10%.The representative of fragrance polyanhydride is to carboxy phenyl propane (p-CPP), content during to carboxy phenyl propane (p-CPP) and the copolymerization of certain herbaceous plants with big flowers diacid is respectively percentage by weight 10-60% and 20-90%, the blend weight ratio is 10-40:50-90, preferably weight ratio 15-30:65-85.
Pharmaceutic adjuvant has a detailed description in " pharmaceutic adjuvant complete works " (the 123rd page, Sichuan science tech publishing house published in 1993, Luo Mingsheng and Gao Tianhui chief editor).In addition, Chinese patent (application number 96115937.5; 91109723.6; 9710703.3; 01803562.0) and U.S.'s patent of invention (patent No. 5,651,986) also enumerated some pharmaceutic adjuvants.Comprise filler, solubilizing agent, absorption enhancer, film former, gellant, system (or causing) hole agent, excipient or inhibitor.Above pharmaceutic adjuvant has has multiple action, and therefore the material of the same race that has is listed in different classifications.The available holder of composition for treating solid tumor of the present invention can be any or multiple material in the above-mentioned pharmaceutic adjuvant, and not exclusively comes the technical characterictic of limit combination according to its classification or definition.
The effective ingredient of entity-tumor-resistant medicine composition can be packaged in the whole pharmaceutic adjuvant equably, also can be packaged in carrier holder center or its surface; Can effective ingredient be discharged by direct diffusion or through mode or dual mode like this that polymer is degraded.In addition, the effective ingredient of composition for treating solid tumor also can be packaged in the liposome equably, or makes microsphere with art methods.
Characteristics of the present invention are that used pharmaceutic adjuvant removes the high molecular polymerization beyond the region of objective existence, also contain above-mentioned any one or multiple other pharmaceutic adjuvant.The pharmaceutic adjuvant that adds is referred to as additive.Additive can be divided into filler, porogen, excipient, dispersant, isotonic agent, preservative agent, inhibitor, solubilizing agent, absorption enhancer, film former, gellant etc. according to its function.
Pharmaceutic adjuvant also can be liquid, as, but be not limited to Oleum sesami, suspension, distilled water, physiology towards liquid and semisolid, as fruit jelly, paste or ointment, above-mentioned pharmaceutic adjuvant is applicable to the compositions that contains or do not contain additive.
Entity-tumor-resistant medicine composition of the present invention can be made into multiple dosage form.As, but be not limited to injection, muddy suspension, ointment, capsule, slow releasing agent, implant, implantation slow release agent etc.; Be different shape, as, but be not limited to granular, lamellar, sphere, bulk, needle-like, bar-shaped and membranaceous.In various dosage forms, based on agent for slow releasing in the body or implant.Above-mentioned dosage form and shape are applicable to the compositions that contains or do not contain additive.
Most preferred dosage form of the present invention is the implantation slow release agent that bio-capacitivity, degradable absorb, and can make different shape because of the clinical needs of difference.The packing method of its Main Ingredients and Appearance and step in United States Patent (USP) (US5651986) have a detailed description, comprise the some kinds of methods that prepare slow releasing preparation: as, but be not limited to, (i) carrier holder powder and medicament mixed be pressed into implant then, promptly so-called mixing method; (ii) carrier holder fusing, mix solid cooled then, promptly so-called fusion method mutually with medicine to be packaged; (iii) the carrier holder is dissolved in the solvent, medicine dissolution to be packaged or be scattered in the polymer solution, evaporating solvent then, the universe is dry, promptly so-called dissolution method; (iv) spray drying method; And (v) freeze-drying etc.Wherein dissolution method can be used for the manufacturing of microsphere, and anticancer pharmaceutical composition also can be packed in the liposome.
Because entity-tumor-resistant medicine composition of the present invention can make the action effect of methods such as conventional chemotherapy, immunization therapy, high thermal therapeutical, photochemical therapy, electrotherapy, Biotherapeutics, hormone therapy, magnetic therapy, ultrasonic therapeutic, radiotherapy and gene therapy strengthen.Therefore when local slow discharges, can share, thereby its anticancer effect is further strengthened with above-mentioned non-operative treatment.
Route of administration
Entity-tumor-resistant medicine composition of the present invention can be through various administrations, as in passages through which vital energy circulates, tremulous pulse, subcutaneous, muscle, Intradermal, intracavity, the tumor, tumor week etc.Route of administration depends on multiple factor, for obtaining valid density in position, tumor place, medicine can give through other number of ways, as arterial perfusion optionally, administration in the intra-bladder instillation (intracavitary), abdominal cavity (intraperitoneal) or thoracic cavity (intrapleural) and canalis spinalis.In number of ways, with topical, as with in selective arterial, the tumor, tumor week injection or be placed as the master, with in the tumor, the form that slowly discharges of tumor week or tumor chamber serve as preferably, can plant slow-releasing pump, slow releasing capsule, slow releasing agent, implant or sustained-release implant as selecting for use.With the tremulous pulse approach is good, directly is placed as the best in the tumor body.
Dosage
The consumption of cancer therapy drug depends on several factors, as, gross tumor volume, patient body weight, administering mode, disease progression situation and therapeutic response.Generally speaking, the platinum-like compounds synergist can be 0.01-200 milligrams/kg body weight, with 1-100 milligram/kg body weight is ideal, with 5-80 milligram/kg body weight for the most desirable, platinum-like compounds can be 0.01-100 milligrams/kg body weight, with 1-180 milligram/kg body weight is ideal, with 5-50 milligram/kg body weight for the most desirable.
Entity-tumor-resistant medicine composition of the present invention can be used to prepare the medicine of the various entity tumors for the treatment of the people, comprises former or cancer or sarcoma or the carcinosarcoma that shifts originating from brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, body of gland, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon, rectum.
Entity-tumor-resistant medicine composition of the present invention also can be used for the treatment of the medicine of the various entity tumors of house pet and animal, when being used for the treatment of the various entity tumor of house pet and animal, the material of species specificity is preferably selected in the active ingredient of entity-tumor-resistant medicine composition of the present invention for use..
Also can add other medicinal ingredient in the entity-tumor-resistant medicine composition of the present invention, as, but be not limited to antibiotics, antalgica, anticoagulant medicine, hemorrhage etc.Above medicinal ingredient can singly select or multiselect, can join the compositions that contains or do not contain additive, and its content is because of specifically deciding.
Above-mentioned effective ingredient is packaged in the pharmaceutic adjuvant, then topical application.Said composition can with topical, wherein be released to the best with local slow again as injection in selective arterial injection and the direct tumor body for good through various administrations.When used the part, composition for treating solid tumor of the present invention can directly place around former or the entity tumor that shifts or in the tumor body, also can directly place former or all or part of excision of entity tumor shifted formed intracavity afterwards.
Entity-tumor-resistant medicine composition Main Ingredients and Appearance of the present invention is a holder with the bio-capacitivity material, so do not cause foreign body reaction.Support to place in the object back degradable and absorb, so no longer operation is taken out.Cause discharges contained drug at tumor by local, thereby optionally improves and prolong local drug concentration, can reduce the general toxic reaction that is caused by the conventional route administration simultaneously.
The characteristics of entity-tumor-resistant medicine composition technology of preparing of the present invention are platinum-like compounds is packaged in the pharmaceutic adjuvant, proportionally with the dissolving of active ingredient and pharmaceutic adjuvant, treat after the abundant mixing dryly, are shaped immediately after the drying and sterilize packing.
Above platinum-like compounds is local to be placed, not only can overcome the toxic reaction that the whole body administration brings, and has solved the tumor by local drug level and cross the low and cell sensitive question to medicine.
By following test and embodiment composition for treating solid tumor of the present invention is further described:
The external tumor-inhibiting action of test one, platinum-like compounds and synergist thereof.
Used tumor cell comprises CNS-1, C6,9L, gastric gland epithelial cancer (SA), bone tumor (BC), breast carcinoma (BA), pulmonary carcinoma (LH), papillary adenocarcinoma of thyroid (PAT), hepatocarcinoma etc.Following platinum-like compounds and synergist thereof are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its tumor growth suppresses effect and is shown in Table 1.
Table 1
Oncocyte (A) (B) (C) (D) (E) (A)? +(B) (A)? +(C) (A)? +(D) (A)? +(E)
CNS 68％ 64％ 66％ 64％ 60％ 90％ 92％ 80％ 94％
C6 62％ 64％ 60％ 64％ 63％ 96％ 94％ 86％ 92％
SA 58％ 60％ 56％ 60％ 62％ 86％ 85％ 86％ 86％
BC 54％ 64％ 54％ 54％ 54％ 94％ 94％ 84％ 94％
BA 54％ 62％ 62％ 52％ 52％ 98％ 96％ 98％ 98％
LH 60％ 58％ 62％ 68％ 66％ 90％ 90％ 94％ 92％
PAT 54％ 56％ 66％ 66％ 69％ 94％ 92％ 94％ 92％
Annotate: (A): cisplatin, platinum-like compounds; (B): paclitaxel, (C): Docetaxel, (D): amycin, (E): 5-fluorouracil.(B)-(E) be the platinum-like compounds synergist, platinum-like compounds is all had notable synergistic effect (P＜0.05).
The external tumor-inhibiting action of test two, platinum-like compounds and synergist thereof.
Used tumor cell is with test one.Following platinum-like compounds and synergist thereof are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its tumor growth suppresses effect and is shown in Table 2.
Table 2
Oncocyte (A) (B) (C) (D) (E) (A)? +(B) (A)? +(C) (A)? +(D) (A)? +(E)
CNS 68％ 64％ 66％ 64％ 60％ 90％ 92％ 80％ 94％
C6 62％ 64％ 60％ 64％ 63％ 96％ 94％ 86％ 92％
SA 58％ 60％ 56％ 60％ 62％ 86％ 85％ 86％ 86％
BC 54％ 64％ 54％ 54％ 54％ 94％ 94％ 84％ 94％
BA 54％ 62％ 62％ 52％ 52％ 98％ 96％ 98％ 98％
LH 60％ 58％ 62％ 68％ 66％ 90％ 90％ 94％ 92％
PAT 54％ 56％ 66％ 66％ 69％ 94％ 92％ 94％ 92％
Annotate: (A): carboplatin, platinum-like compounds; (B): mitoxantrone, (C): ametycin, (D): epirubicin, (E): pemetrexed.(B)-(E) be the platinum-like compounds synergist, platinum-like compounds is all had notable synergistic effect (P＜0.05).
The external tumor-inhibiting action of test three, platinum-like compounds and synergist thereof.
Used tumor cell is with test one.Following platinum-like compounds and synergist thereof are added in 24 hours the various tumor cells of In vitro culture by 10ug/ml concentration, continue to cultivate counting cells sum after 48 hours.Its tumor growth suppresses effect and is shown in Table 3.
Table 3
Oncocyte (A) (B) (C) (D) (E) (A)? +(B) (A)? +(C) (A)? +(D) (A)? +(E)
CNS 68％ 64％ 66％ 64％ 60％ 90％ 92％ 80％ 94％
C6 62％ 64％ 60％ 64％ 63％ 96％ 94％ 86％ 92％
SA 58％ 60％ 56％ 60％ 62％ 86％ 85％ 86％ 86％
BC 54％ 64％ 54％ 54％ 54％ 94％ 94％ 84％ 94％
BA 54％ 62％ 62％ 52％ 52％ 98％ 96％ 98％ 98％
LH 60％ 58％ 62％ 68％ 66％ 90％ 90％ 94％ 92％
PAT 54％ 56％ 66％ 66％ 69％ 94％ 92％ 94％ 92％
Annotate: (A): oxaliplatin, platinum-like compounds; (B): bleomycin, (C): Ismipur, (D): Rumi Qu Sai, (E): methotrexate.(B)-(E) be the platinum-like compounds synergist, platinum-like compounds is all had notable synergistic effect (P＜0.05).
Above-mentioned experimental result shows that the platinum-like compounds synergist all has the notable synergistic effect to platinum-like compounds.Further test shows, other platinum-like compounds synergist that the present invention is listed, as, carmofur, ftorafur, cytosine arabinoside, gemcitabine, thunder for song account for, Raltitrexed, dexrazoxane etc. to cisplatin, carboplatin, dexormaplatin, heptan platinum-like compounds such as platinum and oxaliplatin the notable synergistic effect is all arranged.Though this is unexpected discovery the of the present invention, is of universal significance.
Tumor-inhibiting action in the body of test four, platinum-like compounds and platinum-like compounds synergist.
With the rat is subjects, with 2x10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it 10 groups (seeing Table 4).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of platinum-like compounds and platinum-like compounds synergist is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 4) on the 30th day.
Table 4
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 62.5±12cm 3
2(6) Oxaliplatin 44±10cm 3 <0.05
3(6) Methotrexate 41±8cm 3 <0.01
4(6) Paclitaxel 34±6cm 3 <0.01
5(6) Docetaxel 38±6.4cm 3 <0.01
6(6) 5-fluorouracil 36±6.8cm 3 <0.01
7(6) Oxaliplatin+methotrexate 22±4.6cm 3 <0.001
8(6) Oxaliplatin+paclitaxel 16±3.6cm 3 <0.001
9(6) Oxaliplatin+Docetaxel 14±4.6cm 3 <0.001
10(6) Oxaliplatin+5-fluorouracil 18±2.6cm 3 <0.001
Above platinum-like compounds synergist all has notable synergistic effect (P＜0.001) to platinum-like compounds.
Tumor-inhibiting action in the body of test five, platinum-like compounds and platinum-like compounds synergist.
With the rat is subjects, with 2x10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it 10 groups (seeing Table 5).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of platinum-like compounds and platinum-like compounds synergist is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 5) on the 30th day.
Table 5
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 66.5±13cm 3
2(6) Carboplatin 46±11cm 3 <0.05
3(6) Pemetrexed 43±8.4cm 3 <0.01
4(6) Rumi Qu Sai 36±6.2cm 3 <0.01
5(6) Carmofur 40±6.46cm 3 <0.01
6(6) Ftorafur 34±6.8cm 3 <0.01
7(6) Cisplatin+pemetrexed 24±4.6cm 3 <0.001
8(6) Cisplatin+Rumi Qu Sai 19±3.6cm 3 <0.001
9(6) Cisplatin+carmofur 18±4.6cm 3 <0.001
10(6) Cisplatin+ftorafur 14±2.6cm 3 <0.001
Above platinum-like compounds synergist all has notable synergistic effect (P＜0.001) to platinum-like compounds.
Tumor-inhibiting action in the body of test six, platinum-like compounds and platinum-like compounds synergist.
With the rat is subjects, with 2x10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it 10 groups (seeing Table 6).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of platinum-like compounds and platinum-like compounds synergist is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 6) on the 30th day.
Table 6
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 66.5±13cm 3
2(6) Heptan platinum 48±10cm 3 <0.05
3(6) Cytosine arabinoside 45±8cm 3 <0.01
4(6) Gemcitabine 38±6cm 3 <0.01
5(6) Thunder accounts for for song 42±6.4cm 3 <0.01
6(6) Raltitrexed 40±6.8cm 3 <0.01
7(6) Heptan platinum+cytosine arabinoside 26±4.6cm 3 <0.001
8(6) Heptan platinum+gemcitabine 20±3.6cm 3 <0.001
9(6) Heptan platinum+Docetaxel 18±4.6cm 3 <0.001
10(6) Heptan platinum+5-fluorouracil 20±2.6cm 3 <0.001
Above platinum-like compounds synergist all has notable synergistic effect (P＜0.001) to platinum-like compounds.
Tumor-inhibiting action in the body of test seven, platinum-like compounds and platinum-like compounds synergist.
With the rat is subjects, with 2x10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it 10 groups (seeing Table 7).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of platinum-like compounds and platinum-like compounds synergist is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 7) on the 30th day.
Table 7
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 66.5±13cm 3
2(6) Cisplatin 46±10cm 3 <0.05
3(6) Amycin 42±6cm 3 <0.01
4(6) Daunomycin 48±86cm 3 <0.01
5(6) Aclarubicin 40±6.4cm 3 <0.01
6(6) Epirubicin 42±6.8cm 3 <0.01
7(6) Cisplatin+amycin 25±3.6cm 3 <0.001
8(6) Cisplatin+epirubicin 21±3.8cm 3 <0.001
9(6) Cisplatin+aclarubicin 18±4.4cm 3 <0.001
10(6) Cisplatin+daunomycin 21±2.4cm 3 <0.001
Above platinum-like compounds synergist all has notable synergistic effect (P＜0.001) to platinum-like compounds.
Tumor-inhibiting action in the body of test eight, platinum-like compounds and platinum-like compounds synergist.
With the rat is subjects, with 2x10 5Individual tumor cell subcutaneous injection is in its hypochondrium, treats that tumor growth after 14 days is divided into it 10 groups (seeing Table 8).First group is contrast, and the 2nd to 10 group is the treatment group.The dosage of platinum-like compounds and platinum-like compounds synergist is 5mg/kg.The treatment back was measured gross tumor volume size, relatively therapeutic effect (seeing Table 8) on the 30th day.
Table 8
Test group (n) Suffered treatment Gross tumor volume (cm 3) The P value
1(6) Contrast 62.5±12cm 3
2(6) Oxaliplatin 44±10cm 3 <0.05
3(6) Mitoxantrone 41±8cm 3 <0.01
4(6) Ametycin 34±6cm 3 <0.01
5(6) Valrubicin 38±6.4cm 3 <0.01
6(6) Pirarubicin 36±6.8cm 3 <0.01
7(6) Oxaliplatin+mitoxantrone 22±4.6cm 3 <0.001
8(6) Oxaliplatin+ametycin 168±3.6cm 3 <0.001
9(6) Oxaliplatin+Valrubicin 16±4.6cm 3 <0.001
10(6) Oxaliplatin+pirarubicin 16±2.6cm 3 <0.001
Above platinum-like compounds synergist all has notable synergistic effect (P＜0.001) to platinum-like compounds.
To sum up, the platinum-like compounds synergist among the present invention all has the notable synergistic effect to platinum-like compounds.Therefore, the effective ingredient of entity-tumor-resistant medicine composition of the present invention is the associating of any one or multiple platinum-like compounds synergist and any one or multiple platinum-like compounds or packing separately.The entity-tumor-resistant medicine composition that contains above effective ingredient can be made into any dosage form or shape, but with agent for slow releasing or to implant dosage form serve as preferred.
The preparation method of entity-tumor-resistant medicine composition of the present invention is as follows:
1. the pharmaceutic adjuvant of weighing is put into container, it is even to add organic dissolution with solvents, and the not strict qualification of the amount of organic solvent is suitable fully to be dissolved as.
2. adding the anticancer active ingredient of weighing by above-mentioned percentage by weight shakes up again.
3. removal organic solvent.Vacuum drying or cold drying all can.
4. dried solid composite is made different shape as required.
5. ray sterilizing (roentgendosis is different because of volume) is standby after the packing.Also available other method sterilization.
(4) specific embodiment
Embodiment 1.
With the 80mg molecular weight is that 10000 the polyglycolic acid and the copolymer (PLGA) of hydroxyacetic acid are put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 10mg oxaliplatin and 10mg ametycin, shakes up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 10% oxaliplatin and 10% ametycin.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 2.
The method that is processed into entity-tumor-resistant medicine composition is identical with embodiment 1, and different is that contained anticancer effective component is:
(A) cisplatin of 1-50%, carboplatin, heptan platinum, DNA-2114, enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, nedaplatin, ormaplatin, sebriplatin, spiroplatin, the paclitaxel of oxaliplatin or zeniplatin and 1-50%, docetaxel, 2 '-hydroxyl taxol, 10-removes the acetyl Baccatine III, 14 beta-hydroxies-10-removes the acetyl Baccatine III, 9-dihydro-13-Baccatine III, IDN5109,10-removes the acetyl taxol, 7-table-taxol, Tetraol, the combination of Baccatine III or Tetraol V; Or
(B) cisplatin of 1-50%, carboplatin, heptan platinum, DNA-2114, enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, nedaplatin, ormaplatin, sebriplatin, spiroplatin, oxaliplatin or zeniplatin and 1-50% bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine help the combination of star; Or
(C) cisplatin of 1-50%, carboplatin, heptan platinum, DNA-2114, enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, nedaplatin, ormaplatin, sebriplatin, spiroplatin, the Ismipur of oxaliplatin or zeniplatin and 1-50%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the combination of cladribine and pentoside.Below all be weight percentage.
Embodiment 3.
With the 80mg molecular weight is that 20000 the polyglycolic acid and the copolymer (PLGA) of hydroxyacetic acid are put into container, adds 100 milliliters of dichloromethane, behind the dissolving mixing, adds 10mg cisplatin and 10mg amycin, shakes up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 10% cisplatin and 10% amycin.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 4. is as described in the embodiment 3, and different is that contained anticancer effective component is:
(a) cisplatin of 5-30%, carboplatin, heptan platinum, DNA-2114, enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, nedaplatin, ormaplatin, sebriplatin, spiroplatin, the paclitaxel of oxaliplatin or zeniplatin and 5-30%, docetaxel, 2 '-hydroxyl taxol, 10-removes the acetyl Baccatine III, 14 beta-hydroxies-10-removes the acetyl Baccatine III, 9-dihydro-13-Baccatine III, IDN5109,10-removes the acetyl taxol, 7-table-taxol, Tetraol, the combination of Baccatine III or Tetraol V; Or
(b) cisplatin of 5-30%, carboplatin, heptan platinum, DNA-2114, enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, nedaplatin, ormaplatin, sebriplatin, spiroplatin, oxaliplatin or zeniplatin and 5-30% bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine help the combination of star; Or
(c) cisplatin of 5-30%, carboplatin, heptan platinum, DNA-2114, enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, nedaplatin, ormaplatin, sebriplatin, spiroplatin, the Ismipur of oxaliplatin or zeniplatin and 5-30%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the combination of cladribine and pentoside.Below all be weight percentage.
Embodiment 5.
80mg polifeprosan (to carboxy phenyl propane: certain herbaceous plants with big flowers diacid weight ratio is 20:80) copolymer is put into container, add 100 milliliters of dichloromethane, behind the dissolving mixing, add 10mg carboplatin and 10mg epirubicin, shake up the dry organic solvent of removing of final vacuum again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain the entity-tumor-resistant medicine composition of 10% card cisplatin and 10% epirubicin.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 6. is as described in the embodiment 5, and different is that contained anticancer effective component is:
(a) cisplatin of 5-30%, carboplatin, heptan platinum, dexormaplatin or the paclitaxel of oxaliplatin and 5-30%, the combination of docetaxel or 2 '-hydroxyl taxol; Or
(b) cisplatin of 5-30%, carboplatin, heptan platinum, dexormaplatin or oxaliplatin and with the combination of bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or the chlorine assistant star of 5-30%; Or
(c) cisplatin of 5-30%, carboplatin, heptan platinum, dexormaplatin or oxaliplatin and 5-30% Ismipur, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, methotrexate, carmofur, ftorafur, cytosine arabinoside, hydroxyurea, gemcitabine, fludarabine, thunder for bently account for, the combination of Raltitrexed, atropic cytidine, dexrazoxane or cladribine.Below all be weight percentage.
Embodiment 7.
(EVAc) puts into container with the 80mg ethylene vinyl acetate copolymer, add 100 milliliters of dichloromethane dissolving mixings after, adds 10 milligrams of carboplatins and 10mg mitoxantrone, shake up the dry removal of final vacuum organic solvent again.Dried solid composite is shaped immediately, and ray sterilizing after the packing must contain 10% carboplatin and 10% mitoxantrone entity-tumor-resistant medicine composition.All be weight percentage.The drug release time of this entity-tumor-resistant medicine composition in external normal saline is 15-20 days, is 30-40 days at the subcutaneous drug release time of mice.
Embodiment 8. is as described in the embodiment 7, but different is that contained anticancer effective component is:
(a) cisplatin of 1-20%, carboplatin, heptan platinum, enloplatin, dexormaplatin or the paclitaxel of oxaliplatin and 1-40%, the combination of docetaxel or 2 '-hydroxyl paclitaxel;
(b) cisplatin of 1-20%, carboplatin, heptan platinum, enloplatin, dexormaplatin or oxaliplatin and 1-40% the combination of bleomycin, daunomycin, amycin, epirubicin, pirarubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star;
(c) cisplatin of 1-20%, carboplatin, heptan platinum, enloplatin, the Ismipur of dexormaplatin or oxaliplatin and 1-40%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the combination of cladribine and pentoside.Below all be weight percentage.
Embodiment 9. is as described in embodiment 1,3,5 or 7, used pharmaceutic adjuvant is respectively one of following or its combination that different is:
A) molecular weight is the polylactic acid (PLA) of 5000-15000,10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the polyglycolic acid of 5000-15000,10000-20000,25000-35000 or 30000-50000 and the copolymer of hydroxyacetic acid (PLGA);
C) ethylene vinyl acetate copolymer (EVAc);
D) to the copolymer (polifeprosan) of carboxy phenyl propane and certain herbaceous plants with big flowers diacid, to carboxy phenyl propane: certain herbaceous plants with big flowers diacid weight ratio is 10:90,20:80,30:70,40:60,50:50 or 60:40;
E) xylitol, oligosaccharide, chitin, potassium salt, sodium salt, hyaluronic acid, collagen protein, gelatin or albumin.
Embodiment 10. is as described in embodiment 1,3,5 or 7, and anticancer effective component that different is is one of following:
(a) combination of 10% cisplatin and 10% 5-fluorouracil;
(b) combination of 10% cisplatin and 10% methotrexate;
(c) combination of 10% cisplatin and 10% gemcitabine;
(d) combination of 10% cisplatin and 10% pemetrexed;
(e) combination of 10% cisplatin and 10% amycin;
(f) combination of 10% cisplatin and 10% epirubicin;
(g) combination of 10% cisplatin and 10% pirarubicin;
(h) combination of 10% cisplatin and 10% ametycin;
(i) combination of 10% cisplatin and 10% mitoxantrone;
(j) combination of 10% cisplatin and 10% paclitaxel;
(k) combination of 10% cisplatin and 10% docetaxel;
(l) combination of 10% cisplatin and 2 '-hydroxyl paclitaxel of 10%.
Below all be weight percentage.
Embodiment 11. is composition for treating solid tumor inside and outside release characteristics relatively
Get the composition for treating solid tumor among the embodiment 10, be placed on respectively in the room temperature normal saline and soak, survey the different time release amount of medicine, calculate external accumulative total and discharge percent (%).It is subcutaneous to be put in white mice, regularly takes out and surveys medicament contg, according to the residual drug amount, calculates the interior accumulative total of body and discharges percent (%).The result shows, the different pharmaceutical release in vitro no significant difference that tries discharged the about 20%, the 14th day and discharges 85-90% in first day.Try to discharge in the different pharmaceutical body also no significant difference, discharged the about 10%, 28th day and discharge more than 98% in first day.But the inside and outside discharges notable difference is arranged, release in vitro is fast than being released in the body.Can keep one month in vivo.

Claims (3)

1. an entity-tumor-resistant medicine composition comprises anticancer effective component and slow-release auxiliary material, it is characterized in that said composition is the implantation slow release agent; Slow-release auxiliary material is selected from bio-capacitivity macromolecule polymer and composition thereof or copolymer; Anticancer effective component is platinum-like compounds and platinum-like compounds synergist, and wherein, the platinum-like compounds synergist is one of paclitaxel kind anti-cancer drugs thing, antitumor antibiotics or antimetabolitas or combination;
Described platinum-like compounds is selected from one of following or combination:
Cisplatin, carboplatin, heptan platinum, DNA-2114, enloplatin, sulfatodiamino cyclohexane platinum, Spiroplatin, dexormaplatin, iproplatin, lobaplatin, rice platinum, nedaplatin, ormaplatin, oxaliplatin, sebriplatin, spiroplatin or zeniplatin;
Described paclitaxel kind anti-cancer drugs thing is selected from one of following or combination:
Paclitaxel, docetaxel, 2 '-hydroxyl taxol, 10-go acetyl Baccatine III, 14 beta-hydroxies-10-to go acetyl Baccatine III, 9-dihydro-13-Baccatine III, 10-to remove acetyl taxol, 7-table-taxol, Tetraol, Baccatine III or Tetraol V;
Described antitumor antibiotics is selected from one of following or combination:
Bleomycin, daunomycin, aclarubicin, amycin, epirubicin, pirarubicin, Valrubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star;
Described antimetabolitas is selected from one of following or combination:
Ismipur, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, cladribine or pentoside;
The macromolecule polymer of described bio-capacitivity, the mixture of macromolecule polymer or copolymer are selected from one of following or its combination:
A) molecular weight is the polylactic acid of 5000-15000,10000-20000,20000-35000 or 30000-50000;
B) molecular weight is the polyglycolic acid of 5000-15000,10000-20000,25000-35000 or 30000-50000 and the copolymer of hydroxyacetic acid;
C) ethylene vinyl acetate copolymer; Or
D) to the copolymer of carboxy phenyl propane and decanedioic acid, to carboxy phenyl propane: the decanedioic acid weight ratio is 10:90,20:80,30:70,40:60,50:50 or 60:40;
E) xylitol, oligosaccharide, chitin, hyaluronic acid, collagen protein, gelatin or albumin.
2. the entity-tumor-resistant medicine composition according to claim 1 is characterized in that the effective ingredient of this anti-cancer composition is:
(a) cisplatin of 1-20%, carboplatin, heptan platinum, enloplatin, dexormaplatin or the paclitaxel of oxaliplatin and 1-40%, the combination of docetaxel or 2 '-hydroxyl paclitaxel;
(b) cisplatin of 1-20%, carboplatin, heptan platinum, enloplatin, dexormaplatin or oxaliplatin and 1-40% the combination of bleomycin, daunomycin, amycin, epirubicin, pirarubicin, ametycin, actinomycin D, losoxantrone, mitoxantrone, piroxantrone, teloxantrone or chlorine assistant star;
(c) cisplatin of 1-20%, carboplatin, heptan platinum, enloplatin, the Ismipur of dexormaplatin or oxaliplatin and 1-40%, 5-fluorouracil, pemetrexed, pemetrexed disodium, Rumi Qu Sai, doxifluridine, floxuridine, mercaptopurine, thioguanine, methotrexate, methotrexate, carmofur, ftorafur, galocitabine, ibacitabine, enocitabine, ancitabine, decitabine, flurocitabine, enocitabine, his shore of imidazoles, GR 30921X, mitotane, cytosine arabinoside, hydroxyurea, the 5-fluorouracil nucleoside, capecitabine, gemcitabine, fludarabine, thunder accounts for for song, Raltitrexed, the atropic cytidine, dexrazoxane, the combination of cladribine and pentoside;
Below all be weight percentage.
3. the entity-tumor-resistant medicine composition according to claim 1 is used to prepare the medicine that treatment originates from cancer, sarcoma or the carcinosarcoma of people and animal brain, central nervous system, kidney, liver, gallbladder, incidence, oral cavity, thyroid, skin, mucosa, blood vessel, osseous tissue, lymph node, lungs, esophagus, stomach, mammary gland, pancreas, eyes, nasopharynx part, uterus, ovary, endometrium, cervix uteri, prostate, bladder, colon or rectum former or secondary.
CNB2005100422610A 2005-04-06 2005-04-06 Anti tumour medicinal composition containing platinum compound Expired - Fee Related CN100500219C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2005100422610A CN100500219C (en) 2005-04-06 2005-04-06 Anti tumour medicinal composition containing platinum compound

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2005100422610A CN100500219C (en) 2005-04-06 2005-04-06 Anti tumour medicinal composition containing platinum compound

Publications (2)

Publication Number Publication Date
CN1686554A CN1686554A (en) 2005-10-26
CN100500219C true CN100500219C (en) 2009-06-17

Family

ID=35304596

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2005100422610A Expired - Fee Related CN100500219C (en) 2005-04-06 2005-04-06 Anti tumour medicinal composition containing platinum compound

Country Status (1)

Country Link
CN (1) CN100500219C (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100464736C (en) * 2006-03-17 2009-03-04 山东蓝金生物工程有限公司 Slow released anticancer injection with both antimetabolite and its synergist
CN104352518A (en) * 2014-10-22 2015-02-18 王喜功 Orally-taken chemotherapy tablet for treating stomach cancer
WO2016205785A1 (en) * 2015-06-19 2016-12-22 Syn-Nat Products Enterprise LLC Pharmaceutical composition of carboplatin based co-crystals and use thereof
CN114081885B (en) * 2022-01-10 2022-04-22 广东工业大学 Application of dexrazoxane in preparation of medicine for preventing or treating adverse reaction caused by platinum chemotherapy drugs in chemotherapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208616A (en) * 1997-08-15 1999-02-24 安徽中人科技有限责任公司 Sustained release and implantation type cis-platinum medicine and method for preparing same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1208616A (en) * 1997-08-15 1999-02-24 安徽中人科技有限责任公司 Sustained release and implantation type cis-platinum medicine and method for preparing same

Also Published As

Publication number Publication date
CN1686554A (en) 2005-10-26

Similar Documents

Publication Publication Date Title
CN100500219C (en) Anti tumour medicinal composition containing platinum compound
CN100374160C (en) Anti-cancer medicine composition containing antimetabolite
CN100350974C (en) Anticarcinogen composition
CN100500212C (en) Anti entity tumour medicinal composition
CN100500218C (en) Anti tumour medicinal composition
CN1923173B (en) Anti-cancer drugs slow release agent comprising anticancer antibiotics and synergist thereof
CN100431606C (en) Anti-cancer medicine composition
CN1846672A (en) Anticancer medicine composition containing antimetabolite
CN100500216C (en) Anti entity tumour medicinal composition containing dichloro ethamine kind drug
CN100998553A (en) Compound anticarcinogen slow-release preparation containing vasoinhibitor
CN100453118C (en) Antientity tumour medicinal composition containing topoenzyme inhibitor
CN100563711C (en) A kind of slow-releasing anticarcinogen injection
CN100431608C (en) Anti entity tumour medicinal composition containing tetrazine kind compound
CN101244272B (en) Anti-solid tumors pharmaceutical combination containing topological enzyme inhibitor
CN1857723A (en) Slow released anticancer medicine preparation with both amrubicin and its synergist
CN101637444B (en) Anti-cancer drug slow release injection containing gemcitabine
CN100431605C (en) Anticarcinogen composition
CN101327185A (en) Anticancer sustained-release implantation agent
CN101371821A (en) Anti-cancer medicine composition containing metabolism-resistance medicament
CN101244271A (en) Anti-solid tumors pharmaceutical combination containing topological enzyme inhibitor
CN1923284A (en) Anti-cancer drug slow release injection and uses thereof
CN100340297C (en) Anticarcinogenic internal implant agent
CN101066451A (en) Solid tumor treating medicine composition containing dicloethamine
CN101066452A (en) Solid tumor treating medicine composition containing
CN100431607C (en) Medicinal composition for tumor body

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee
CP02 Change in the address of a patent holder

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Co-patentee after: Kong Qingzhong

Patentee after: Shandong Lanjin Pharmaceuticals Co., Ltd.

Address before: 250100 No. 69, building 7, Pioneer Park, Huayang Road, Ji'nan hi tech Development Zone, Shandong, -802

Co-patentee before: Kong Qingzhong

Patentee before: Shandong Lanjin Pharmaceuticals Co., Ltd.

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: KONG QINGZHONG

Owner name: SHANDONG ENDUO BIOPHARMACEUTICAL CO., LTD.

Free format text: FORMER OWNER: SHANDONG LANJIN BIOENGINEERING CO., LTD.

Effective date: 20110421

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: 250101 NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI'NAN CITY, SHANDONG PROVINCE TO: 250101 201, NO. 1750, TIANCHEN ROAD, HIGH-TECH. ZONE, JI'NAN CITY, SHANDONG PROVINCE

TR01 Transfer of patent right

Effective date of registration: 20110421

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 201

Patentee after: Shandong many biological pharmaceutical Co., Ltd.

Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750

Co-patentee before: Kong Qingzhong

Patentee before: Shandong Lanjin Pharmaceuticals Co., Ltd.

C56 Change in the name or address of the patentee

Owner name: DASEN BIOPHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME: SHANDONG ENDUO BIOLOGICAL PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 201

Patentee after: DASEN BIOLOGICAL PHARMACEUTICAL CO., LTD.

Address before: High tech Zone Tianchen road Ji'nan City, Shandong province 250101 No. 1750 201

Patentee before: Shandong many biological pharmaceutical Co., Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20090617

Termination date: 20160406